First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Arrowhead Pharmaceuticals, Inc. (ARWR): the developments shaping its investment case

    Follow the evidence affecting Arrowhead Pharmaceuticals, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Arrowhead Pharmaceuticals, Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-06 · 2 reports
    Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGR
    Channel: Potential future revenue streams if their investigational RNAi therapeutic for atopic dermatitis (ARO-AD1) progresses through clinical trials and gains market approval, benefiting from the expanding market.
    watch· 1-5y
    2026-09-25 · 4 reports
    ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share
    Channel: Increased competition in the siRNA therapeutic space, potential for new comparative data.
    mixed· 3-12m
    2026-09-24
    Kyverna Therapeutics, Inc. to Complete Rolling BLA Submission for Miv-cel in Q4 2026
    Channel: Second-order effect: Kyverna's miv-cel uses an autologous CAR T-cell therapy approach. While not directly competitive, success in CAR T for autoimmune diseases could validate the broader platform and attract investor interest in similar advanced therapy platforms, including RNAi therapies for rare d
    watch· 3-12m

    Event impact log

    10 events mapped to ARWR since 2026-08-19. Evidence through 2026-09-25.

    DateEventChannelDirectionHorizonImpact
    2026-09-25ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per shareIncreased competition in the siRNA therapeutic space, potential for new comparative data.mixed3-12m0.30
    2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqIncreased investor confidence in RNA-based therapeutics and the broader biotech funding environment. ADARx's focus on RNA-targeting therapies could draw attention to similar companies.Bullish1-3m0.30
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per ShareIncreased competition or validation of the siRNA therapeutic platform.watch1-3m0.20
    2026-09-25ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per shareIncreased investor attention and potential competitive landscape shifts within the siRNA therapeutic space.watch1-3m0.30
    2026-09-24Kyverna Therapeutics, Inc. to Complete Rolling BLA Submission for Miv-cel in Q4 2026Second-order effect: Kyverna's miv-cel uses an autologous CAR T-cell therapy approach. While not directly competitive, success in CAR T for autoimmune diseases could validate the broader platform and attract investor interest in similar advanced therapy platforms, including RNAi therapies for rare dwatch3-12m0.30
    2026-09-16Acumen Pharmaceuticals Projects Cash Runway into Early 2027Broader investor sentiment towards clinical-stage biotechnology companies, particularly those with significant R&D burn and reliance on future capital raises. Acumen's cash runway news could be a micro-example of a common biotech challenge.watch3-12m0.10
    2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGRPotential future revenue streams if their investigational RNAi therapeutic for atopic dermatitis (ARO-AD1) progresses through clinical trials and gains market approval, benefiting from the expanding market.watch1-5y0.40
    2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologicsSecond-order effect: Increased investor interest in companies with pipeline assets targeting atopic dermatitis, even if early-stage. Arrowhead has an RNAi therapeutic (ARO-AD1) in preclinical development for atopic dermatitis.watch1-5y0.40
    2026-09-01Valion Bio, Inc. Follow-On — $7.7MArrowhead Pharmaceuticals is another biotech company, though its focus is on RNA interference. The general sentiment around biotech funding, particularly for innovative platforms, could be marginally influenced by such events. This is a very indirect and weak link.watch3-12m0.10
    2026-08-19Vogenx, Inc. IPO — $12MPotential new competitor in RNAi or related genetic medicine space. While not directly mRNA, the broader genetic medicine field is interconnected. A new, well-funded player could influence R&D trends or partnership opportunities.watch3-12m0.20

    Continue this research

    Build your Arrowhead Pharmaceuticals, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the ARWR entity page →

    Research Arrowhead Pharmaceuticals, Inc. · $399/mo